

Innovax-ND-H5 (--) - Concentrate and solvent for suspension for injection

Authorised

- Turkey herpesvirus, strain HVT-ND-H5 (cell-associated), expressing fusion protein gene of Newcastle disease virus and haemagglutinin gene of Avian influenza virus subtype H5, Live

Product identification

Medicine name:

Innovax-ND-H5 (--) - Concentrate and solvent for suspension for injection

Active substance:

Turkey herpesvirus, strain HVT-ND-H5 (cell-associated), expressing fusion protein gene of Newcastle disease virus and haemagglutinin gene of Avian influenza virus subtype H5, Live

Target species:

Chicken

Chicken (embryonated eggs)

Route of administration:

In ovo

Subcutaneous use

Product details

Active substance and strength:

Turkey herpesvirus, strain HVT-ND-H5 (cell-associated), expressing fusion protein gene of Newcastle disease virus and haemagglutinin gene of Avian influenza virus subtype H5, Live

Presentation_strength: $10^{3.3}$ - $10^{4.6}$ Reference: In-house Index: 0

Pharmaceutical form:

Concentrate and solvent for suspension for injection

Withdrawal period by route of administration:

In ovo:

-

Chicken

- Not applicable. 0 day Zero days

-

Chicken (embryonated eggs)

- Not applicable. 0 day Zero days

Subcutaneous use:

-

Chicken

- Not applicable. 0 day Zero days

-

Chicken (embryonated eggs)

- Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI01AD

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:

Packaging:Concentrate: ampoule (glass), Package_size:Concentrate: 1 ampoule,
Content:Concentrate: 2 ml (4000 doses)

Packaging:Concentrate: ampoule (glass), Package_size:Concentrate: 1 ampoule,
Content:Concentrate: 2 ml (2000 doses)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Applications in exceptional circumstances (Article 25 of Regulation (EU) 2019/6)

Marketing authorisation holder:

Intervet International B.V.

Marketing authorisation date:

22/05/2024

Manufacturing sites for batch release:

Intervet International B.V.

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

22/05/2024

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 6/08/2025

[Download](#)

ema-puar-v6362-innovaxndh5-en.pdf